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Intravenous artesunate improves survival in severe malaria,
but clinical trial data from nonendemic countries are scarce.
The TropNet severe malaria database was analyzed to
compare outcomes of artesunate vs quinine treatment. Arte-
sunate reduced parasite clearance time and duration of inten-
sive care unit and hospital treatment in European patients
with imported severe malaria.
Keywords. severe malaria; artesunate; quinine; Plasmodium
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Intravenous artesunate has been shown to be a life-saving drug
for patients with severe malaria in multicenter trials in South-
east Asia and Africa, improving survival compared with quinine
by 34.7% and 22.5%, respectively. The survival beneﬁt was most
pronounced in hyperparasitemic patients [1, 2].
In nonendemic countries where nonimmune travelers with
imported malaria may exhibit high parasite loads, introduction
of intravenous artesunate into treatment practice has been slow
because a formulation meeting standards of Good Manufactur-
ing Practice (GMP) as well as prospective clinical safety data re-
quired for regulatory approval are not available. Intravenous
artesunate is generally safe and well tolerated. A delayed self-
limiting hemolytic reaction can occur several weeks after treat-
ment, making follow-up examinations necessary [3–5].
Given the documented life-saving effect of artesunate in en-
demic countries, controlled clinical trials to conﬁrm better sur-
vival for patients in nonendemic countries are no longer
justiﬁed. Moreover, limited patient numbers and low case fatal-
ity of patients treated under intensive care standards in indus-
trialized countries curtail their feasibility. Observational studies
are therefore the only source of information on artesunate in
this patient population.
The European Network for Tropical Medicine and Travel
Health (TropNet) has conducted an observational multicenter
study over 9 years (2006–2014) to monitor treatment practices
and outcomes of severe malaria treatment across 12 European
countries. For this brief report, data from study patients treated
with intravenous artesunate or intravenous quinine were ana-
lyzed to compare clinical outcomes such as parasite clearance,
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treatment duration in hospital (particularly in the intensive care
unit [ICU]), and survival.
METHODS
All patients with conﬁrmed severe Plasmodium falciparum ma-
laria according to the 2006 World Health Organization criteria
[6] treated at one of the 28 participating TropNet centers be-
tween 2006 and 2014 were eligible for inclusion. The treatment
remained the responsibility of the treating physician. Demo-
graphic, travel, clinical, laboratory, and treatment data were col-
lected retrospectively from clinical records at the treatment
center, pseudonymized, and reported using an electronic case
report form.
The primary objective of this analysis was to analyze differ-
ences among patients treated with intravenous artesunate vs in-
travenous quinine with regard to survival, duration of ICU and
inpatient treatment, and 99% and complete parasite clearance
time. The Mann–Whitney U test at a 2-sided signiﬁcance level
of α = .05 was used for comparative analysis. Data are displayed
as median (interquartile range). To further assess the associa-
tion between treatment with artesunate and ICU treatment
time, multiple regression analysis with backward elimination
(P < .05) was performed, with duration of ICU treatment as a
dependent variable including (1) known risk factors for longer
treatment (age, renal failure, respiratory failure, coma, and the
number of comorbidities); (2) variables with statistically signiﬁ-
cant association with ICU treatment time in univariate analysis;
and (3) the year of treatment. The selected variables were used
as independent variables in multifactor analysis of variance
(ANOVA) of ICU treatment time using the F test.
Statistical analysis was performed using JMP software version
7.0 (SAS Institute Inc, Cary, North Carolina). The study was ap-
proved by the Ethics Committee of Charité University Hospital
Berlin. Ethical clearance for transfer of pseudonymized patient
data was sought at participating TropNet centers according to
local regulations.
RESULTS
The TropNet severe malaria study comprises 185 cases with se-
vere falciparum malaria. The majority of patients were Europe-
an tourists (106/185 [57%]), followed by patients with a history
of migration (68/185 [37%]) and tourists from endemic areas
(11/185 [6%]). The overall 28-day survival rate was 98.4%
(182/185). Of 3 patients who died, 2 had been treated with in-
travenous quinine and 1 with quinine and artesunate simulta-
neously. All deaths occurred within the ﬁrst 4 days after
admission. Due to the low number of deaths, a survival analysis
was not performed. Adverse events in patients treated with qui-
nine consisted of transient cinchonism and hypoglycemia and
were predominantly mild. In 70 patients who received intrave-
nous artesunate, 19 episodes of delayed hemolysis were ob-
served, a known adverse drug reaction [3–5].
For the following analysis of treatment duration and parasite
clearance, patients who died (n = 3), who underwent erythro-
cyte apheresis (n = 5), who were treated with artesunate and
quinine simultaneously (n = 7, 1 of whom also underwent aphe-
resis and 1 of whom died), or who received oral antimalarial
combination therapies as ﬁrst-line treatment (n = 21) were ex-
cluded. Thereafter, 151 patients were available for comparative
analysis, of whom 60 received intravenous artesunate and 91 re-
ceived intravenous quinine as main ﬁrst-line treatment.
Patients treated with either artesunate or quinine showed
similar baseline characteristics such as median age (44 vs 40
years; P = .16), median baseline parasitemia (5% vs 6%; P = .4),
median number of criteria for severe disease (2 in both groups;
P = .3), median proportion of patients with comorbidities (32%
vs 39%; P = .3), median proportion of patients with European
origin (60% vs 55%), history of migration (34% vs 39%), and
visitors from endemic countries (6% in both groups; overall
χ2 = 0.62, P = .73), respectively.
Patients treated with intravenous artesunate exhibited a faster
99% parasite clearance time (median, 36 vs 48 hours; P = .02,
n = 100) and a faster complete parasite clearance time (median,
72 hours vs 96 hours; P = .005, n = 84) compared with patients
treated with intravenous quinine.
Similarly, median length of ICU treatment (2 vs 3 days;
P < .05, n = 117) and median length of hospital inpatient treat-
ment (6 vs 7 days; P < .01, n = 151) were shorter for patients
treated with artesunate compared to patients treated with qui-
nine (Figure 1). Absence of signs of cerebral malaria (median 2
vs 4 days; P < .0001), absence of renal failure (median, 2 vs 4
days; P < .0001), and absence of respiratory failure (median, 2
vs 6 days; P < .0001) were equally associated with a shorter
ICU treatment.
In multiple regression analysis, the same 4 variables were se-
lected in the ﬁnal model and showed independent statistically
signiﬁcant association with shorter length of stay at ICU in
multifactor ANOVA (F = 16.0, df = 4, P < .0001): treatment
with artesunate (F = 6.1, P = .01) compared with quinine, ab-
sence of cerebral malaria (F = 4.33, P = .04), absence of renal
failure (F = 20.0, P < .0001), and absence of respiratory failure
(F = 12.2, P < .001). Age, sex, citizenship (European/history of
migration/visitor from endemic area), year of presentation, hy-
perparasitemia, presence of comorbidities, and multiplicity of
criteria for severe malaria did not show signiﬁcant association
with duration of ICU treatment.
Subgroup analysis revealed that faster parasite clearance
and shorter length of ICU and inpatient treatment for artesu-
nate was only evident in patients presenting with hyper-
parasitemia ≥5% (108/151), whereas in patients without
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hyperparasitemia (43/151), there was no statistically signiﬁcant
difference (Figure 1).
DISCUSSION
This TropNet study is the largest multicenter study outside
endemic areas comparing intravenous quinine vs intravenous
artesunate for the treatment of severe malaria. Only 1 single-
center study from the United Kingdom reported similar data
in a limited number of patients with artesunate treatment [7].
As an overwhelming beneﬁt of artesunate treatment has
already been shown in principle, controlled clinical trials
are no longer justiﬁed. Regulatory approval in industrialized
countries is therefore delayed, preventing patients from having
regular access to the best treatment available. A GMP-compliant
formulation is only available in the United States from the Cen-
ters for Disease Control and Prevention [8]. The present data
may help to improve clinical decision making in nonendemic
countries and provide useful information for regulatory
authorities.
Figure 1. Median time to 99% parasite clearance, median time to total parasite clearance, median length of stay in intensive care unit (ICU), and median
length of stay in hospital in patients treated with either intravenous artesunate or intravenous quinine. Hyperparasitemia is deﬁned as parasitemia ≥5%.
*Statistically signiﬁcant difference. Abbreviation: IQR, interquartile range.
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As observed in endemic countries, intravenous artesunate
cleared high parasitemias in our patient population more rapid-
ly than intravenous quinine. This is of particular relevance for
nonimmune patients who carry a comparatively high risk of hy-
perparasitemia. Knowledge from malaria-endemic settings
shows that survival beneﬁt was most pronounced in hyperpar-
asitemic patients [1, 2].
Our data demonstrate that intravenous artesunate reduces
duration of ICU and hospital treatment. Both factors have rel-
evant inﬂuence on outcome as many patients with severe ma-
laria die from nosocomial complications rather than from
malaria itself [9]. This applies in particular to patients in ICU
treatment with respiratory failure (including comatose patients
with cerebral malaria on mechanical ventilation), in whom the
risk for ventilator-associated infections increases over time [10].
We did not ﬁnd an association of sex, age, or comorbidities
with duration of ICU treatment despite age being a known risk
factor for increased mortality from severe malaria [11]. Shorter
duration of ICU and hospital treatment was only found for pa-
tients with high parasitemia, underlining that rapid parasite
clearance is likely to be a decisive factor for the clinical and
overall beneﬁt of artesunate.
This is a retrospective observational study on a heterogeneous
patient population with inherent limitations. In particular,
biases in physicians’ judgment and patient selection may have
occurred. The proportion of nonhyperparasitemic patients
in our population was comparatively small. The absence of
statistically signiﬁcant different outcomes in these patients
might therefore be caused by type II error. As postartemisinin
delayed hemolysis was ﬁrst described in the year 2011 [3],
underreporting of this adverse reaction may have occurred in
this retrospective study.
In conclusion, this analysis shows that the therapeutic beneﬁt
of artesunate to patients in nonendemic areas is beyond doubt.
Faster parasite clearance is likely to be the relevant factor that
reduces ICU treatment duration, hospital stay, and, therefore,
the risk of nosocomial complications. Prospective collection
of data—for example, in patient registries—should continue
to improve the evidence base on the safety of artesunate in non-
endemic countries.
Notes
Financial support. F. K. is supported by Charité Clinical Scientist Pro-
gram, funded by Charité Universitätsmedizin Berlin and the Berlin Institute
of Health.
Potential conﬂicts of interest. L. V. has received grants and consultation
fees from Sigma-Tau Industrie Farmaceutiche Riunite. All other authors re-
port no potential conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Dondorp A, Nosten F, Stepniewska K, Day N, White N; South East
Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group. Arte-
sunate versus quinine for treatment of severe falciparum malaria: a
randomised trial. Lancet 2005; 366:717–25.
2. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus
quinine in the treatment of severe falciparum malaria in African
children (AQUAMAT): an open-label, randomised trial. Lancet 2010;
376:1647–57.
3. Zoller T, Junghanss T, Kapaun A, et al. Intravenous artesunate for severe
malaria in travelers, Europe. Emerg Infect Dis 2011; 17:771–7.
4. Rolling T, Schmiedel S, Wichmann D, Wittkopf D, Burchard G-D,
Cramer JP. Post-treatment haemolysis in severe imported malaria
after intravenous artesunate: case report of three patients with hyper-
parasitaemia. Malar J 2012; 11:169.
5. Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment
outcome of intravenous artesunate in patients with severe malaria in the
Netherlands and Belgium. Malar J 2012; 11:102.
6. World Health Organization. Guidelines for the treatment of malaria.
Geneva, Switzerland: WHO, 2006.
7. Eder M, Farne H, Cargill T, Abbara A, Davidson RN. Intravenous arte-
sunate versus intravenous quinine in the treatment of severe falciparum
malaria: a retrospective evaluation from a UK centre. Pathog Glob
Health 2012; 106:181–7.
8. Centers for Disease Control and Prevention. Artesunate is available to
treat severe malaria in the United States. Available at: http://www.cdc.gov/
malaria/diagnosis_treatment/artesunate.html. Accessed 28 January 2015.
9. Marks ME, Armstrong M, Suvari MM, et al. Severe imported falcipa-
rum malaria among adults requiring intensive care: a retrospective
study at the hospital for tropical diseases, London. BMC Infect Dis
2013; 13:118.
10. Kohlenberg A, Schwab F, Behnke M, Geffers C, Gastmeier P. Pneumo-
nia associated with invasive and noninvasive ventilation: an analysis of
the German nosocomial infection surveillance system database. Inten-
sive Care Med 2010; 36:971–8.
11. Mühlberger N, Jelinek T, Behrens RH, et al. Age as a risk factor for se-
vere manifestations and fatal outcome of falciparum malaria in Europe-
an patients: observations from TropNetEurop and SIMPID Surveillance
Data. Clin Infect Dis 2003; 36:990–5.
1444 • CID 2015:61 (1 November) • BRIEF REPORT
